MARINUS PHARMACEUTICALS INC (MRNS) Stock Analyst Ratings
USA - NASDAQ:MRNS - US56854Q2003 - Common Stock
0.55 USD
+0 (+0.09%)
0.5491 USD
0 (-0.16%)
ChartMill assigns a Buy % Consensus number of 74% to MRNS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.09. This target is 97.82% above the current price.
MRNS was analyzed by 13 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about MRNS.
In the previous month the buy percentage consensus was at a similar level.
MRNS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-10-25 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-10-25 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-10-25 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-25 | Jefferies | Downgrade | Buy -> Hold |
| 2024-10-25 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-10-24 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-24 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-10-17 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-11 | EF Hutton | Maintains | Buy -> Buy |
| 2024-09-30 | EF Hutton | Initiate | Buy |
| 2024-09-24 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-23 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-23 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-14 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-18 | Truist Securities | Maintains | Buy -> Buy |
| 2024-06-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-17 | Truist Securities | Maintains | Buy -> Buy |
| 2024-04-16 | Baird | Downgrade | Outperform -> Neutral |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-15 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-04-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
MARINUS PHARMACEUTICALS INC / MRNS FAQ
Can you provide the average price target for MARINUS PHARMACEUTICALS INC stock?
13 analysts have analysed MRNS and the average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55.
What is the consensus rating for MRNS stock?
The consensus rating for MARINUS PHARMACEUTICALS INC (MRNS) is 73.8462 / 100 . This indicates that analysts generally have a positive outlook on the stock.